{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-034529","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.172444+00:00","generated_at":"2026-06-04T18:40:33.273675+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eloxx inks exclusive license deal with Almirall for ZKN-013; $3M upfront, up to $470M milestones","bullets":["Upfront payment of $3.0 million; eligible for up to $470.0 million in regulatory and sales milestones.","Tiered royalties on any future global sales of ZKN-013.","ZKN-013 is a Phase I ready oral therapy for nonsense mutations causing rare dermatologic diseases.","Almirall obtains worldwide rights to develop and commercialize ZKN-013."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-034529","json":"https://secwatch.observer/filing/0001104659-24-034529.json","markdown":"https://secwatch.observer/filing/0001104659-24-034529.md","text":"https://secwatch.observer/filing/0001104659-24-034529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/0001104659-24-034529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/tm248887d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T18:40:33.273675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90ba8f6b46360559b50a6fcf527a688d351892d0","claim":"Eloxx Pharmaceuticals, Inc. entered into License Agreement with Almirall, S.A. valued at $3.0 million (effective 2024-03-11).","evidence_excerpt":"entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924034529/0001104659-24-034529-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Almirall, S.A."},{"label":"Value","value":"$3.0 million"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}